Skip to content
Wenlo
Sign in
← Markets

PR Newswire · Press release

INOVIO to Participate in Upcoming Scientific Conferences

INOVIO Pharmaceuticals, Inc.NASDAQ-NMS:INONASDAQ:INO
Industry BIOIndustry HEAIndustry MTCIndustry PHASubject TRISubject FVTSubject TDS

Original release from PR Newswire

As distributed by PR Newswire, unedited.


PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:

Soft Bones Third International Scientific Meeting on Hypophosphatasia (New York)

Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine

Date: Sunday, November 8

World Federation of Hemophilia - New Technology & Gene Therapy (NTGT) Workshop (Montreal)

Presentation: INO-D001 for Hemophilia A

Date: Thursday, November 12

Abstracts and presentations will be added to our events page if available.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com

Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302926885.html

SOURCE INOVIO Pharmaceuticals, Inc.

Originally published by PR Newswire.

Source: INOVIO Pharmaceuticals, Inc.

Copyright © 2026 PR Newswire Association LLC. All Rights Reserved. A Cision company.